The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of modern systemic and multimodality treatments on post-relapse survival in retroperitoneal soft-tissue sarcoma: A digital-twin target trial emulation study.
 
Roberta Sanfilippo
Consulting or Advisory Role - Boehringer Ingelheim; RAIN (Inst)
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); AORG Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi-Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); RAIN (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Andrea Franza
No Relationships to Disclose
 
Gabriele Tinè
No Relationships to Disclose
 
Chiara Fabbroni
No Relationships to Disclose
 
Tommaso Capoccia
No Relationships to Disclose
 
Dario Callegaro
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Paola Collini
No Relationships to Disclose
 
Andrea Vanzulli
No Relationships to Disclose
 
Claudia Sangalli
No Relationships to Disclose
 
Elena Fumagalli
No Relationships to Disclose
 
Pierluigi di Mauro
No Relationships to Disclose
 
Gabriella Greco
No Relationships to Disclose
 
Marco Fiore
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Gentili; GlaxoSmithKline; Peerview; PharmaMar; Servier
Consulting or Advisory Role - Bayer; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; Merck Serono; Orion; Parabilis; Pharmaessentia; SERVIER; Sun Pharma
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Merck Serono; Novartis (Inst); PharmaMar (Inst); SERVIER; SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Paolo Giovanni Casali
No Relationships to Disclose
 
Rosalba Miceli
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar